-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, April 19, with the intensive disclosure of the 2020 annual reports of listed companies, the first quarter of 2021 transcripts will follow.
According to statistics, a total of 110 pharmaceutical companies in A-shares have disclosed their performance in the first quarter.
Three companies including Intech Healthcare and Daan Gene have net profits of over 1 billion yuan; 500 million to 1 billion yuan are Changchun High-tech, Yiling Pharmaceutical, 7 companies including China Resources Sanjiu and Harbin Sanlian; 52 companies including Kelun Pharmaceutical, Haisco and Zuoli Pharmaceutical have doubled, and Hotview Bio has soared 1,000 times, becoming the "pre-increasing king" of performance; Qianhong Pharmaceutical, 18 companies including Jinling Pharmaceutical turned losses into profits.
It is worth mentioning that there are currently 14 companies that are losing money, and only 2 companies are the first to lose money.
In the same period last year, 30 companies are the first to lose money.
Brokerage analysis pointed out that the first quarter of last year was affected by the epidemic and the performance of many listed companies was impacted.
Given the low base last year, it is a general consensus in the market that the performance forecast for the first quarter of this year will be better.
According to statistics, a total of 110 pharmaceutical companies in A-shares have disclosed their performance in the first quarter.
Three companies including Intech Healthcare and Daan Gene have net profits of over 1 billion yuan; 500 million to 1 billion yuan are Changchun High-tech, Yiling Pharmaceutical, 7 companies including China Resources Sanjiu and Harbin Sanlian; 52 companies including Kelun Pharmaceutical, Haisco and Zuoli Pharmaceutical have doubled, and Hotview Bio has soared 1,000 times, becoming the "pre-increasing king" of performance; Qianhong Pharmaceutical, 18 companies including Jinling Pharmaceutical turned losses into profits.
It is worth mentioning that there are currently 14 companies that are losing money, and only 2 companies are the first to lose money.
In the same period last year, 30 companies are the first to lose money.
Brokerage analysis pointed out that the first quarter of last year was affected by the epidemic and the performance of many listed companies was impacted.
Given the low base last year, it is a general consensus in the market that the performance forecast for the first quarter of this year will be better.
A-share pharmaceutical companies' performance in the first quarter of 2021
A-share pharmaceutical company's first quarter 2021 performance report
A-share pharmaceutical companies' performance forecast for the first quarter of 2021
90 % of the first quarter Announcement! 52 companies doubled, 18 companies turned losses, only 2 companies lost first
，A1102021，，15，1，94。、310；5～10、、、7；、、52，1000，“”；、18。，14，2，，30。
，，，，。，，，，，。
20215436，314.
4%；20202535。，，，，，2021。
4%；20202535。，，，，，2021。
，2020，，，2020。，2021，。2950～3800，207%～238%，2761。
、……5！1000
Net profit: 841 million to 895 million yuan
Year-on-year growth: 55% ~ 65%
Regarding the substantial growth in performance in the first quarter, Changchun Hi-tech pointed out that it was mainly due to the income growth of the backbone pharmaceutical companies.
According to the Changchun High New Year Report, the company's operating income in 2020 was 8.
577 billion yuan, a year-on-year increase of 16.
31%; net profit was 3.
047 billion yuan, a year-on-year increase of 71.
64%.
The company and its subsidiaries are operating steadily, and the revenue and net profit of key pharmaceutical companies continue to grow.
Among them, the subsidiary Jinsai Pharmaceutical achieved revenue of 5.
803 billion yuan, a year-on-year increase of 20.
34%, and a net profit of 2.
76 billion yuan, a year-on-year increase of 39.
66%; subsidiary Baike Biotechnology achieved revenue of 1.
433 billion yuan, a year-on-year increase of 43.
30%, and a net profit of 409 million Yuan, a year-on-year increase of 133.
88%.
Ma Ji, chairman of Changchun Hi-tech, stated that “market expansion and innovative R&D” are the company’s primary strategic goals, and the introduction of high-end talents is the focus of internal management.
The market share of the products, the promotion of new indications and the enrichment of the product line.
It is worth mentioning that Beike Biotech’s application for listing on the Science and Technology Innovation Board was approved on February 1 this year, and its prospectus (registration draft) was disclosed on April 2, and it is currently in the registration stage.
According to the Changchun High New Year Report, the company's operating income in 2020 was 8.
577 billion yuan, a year-on-year increase of 16.
31%; net profit was 3.
047 billion yuan, a year-on-year increase of 71.
64%.
The company and its subsidiaries are operating steadily, and the revenue and net profit of key pharmaceutical companies continue to grow.
Among them, the subsidiary Jinsai Pharmaceutical achieved revenue of 5.
803 billion yuan, a year-on-year increase of 20.
34%, and a net profit of 2.
76 billion yuan, a year-on-year increase of 39.
66%; subsidiary Baike Biotechnology achieved revenue of 1.
433 billion yuan, a year-on-year increase of 43.
30%, and a net profit of 409 million Yuan, a year-on-year increase of 133.
88%.
Ma Ji, chairman of Changchun Hi-tech, stated that “market expansion and innovative R&D” are the company’s primary strategic goals, and the introduction of high-end talents is the focus of internal management.
The market share of the products, the promotion of new indications and the enrichment of the product line.
It is worth mentioning that Beike Biotech’s application for listing on the Science and Technology Innovation Board was approved on February 1 this year, and its prospectus (registration draft) was disclosed on April 2, and it is currently in the registration stage.
Yiling Pharmaceutical
Net profit: 677 million to 701 million yuan
Year-on-year growth: 50% ～60%
Yiling Pharmaceutical said that on the one hand, the company's winning the first prize of the National Science and Technology Progress Award has gradually shown its influence on the company's cardiovascular and cerebrovascular products market, and market demand has grown steadily.
At the same time, with the adjustment of the company’s sales strategy and the completion of the optimization of the marketing organization structure, sales revenue has achieved substantial year-on-year growth; on the other hand, the brand awareness of Lianhua Qingwen’s products has been greatly improved, the market share has continued to increase, and sales revenue has achieved a higher level than the same period last year.
Good growth.
A few days ago, the Phase III clinical trial program of Yiling Pharmaceutical's 1.
1 category innovative drug aniprofen injection for the treatment of postoperative moderate and severe pain completed the registration and publicity of the CDE drug clinical trial registration and information disclosure platform, and the phase III clinical trial can be initiated.
test.
At the same time, with the adjustment of the company’s sales strategy and the completion of the optimization of the marketing organization structure, sales revenue has achieved substantial year-on-year growth; on the other hand, the brand awareness of Lianhua Qingwen’s products has been greatly improved, the market share has continued to increase, and sales revenue has achieved a higher level than the same period last year.
Good growth.
A few days ago, the Phase III clinical trial program of Yiling Pharmaceutical's 1.
1 category innovative drug aniprofen injection for the treatment of postoperative moderate and severe pain completed the registration and publicity of the CDE drug clinical trial registration and information disclosure platform, and the phase III clinical trial can be initiated.
test.
China Resources Sanjiu
Net profit: 600 million to 710 million yuan
Year- on-year growth: 12.
5% ～33.
13%
5% ～33.
13%
Regarding the performance growth in the first quarter, China Resources Sanjiu stated that the company conformed to the development trend of the industry, continued to carry out innovation, transformation and upgrading, continuously optimized product structure, strengthened brand building, and promoted profitability.
Recently, China Resources Sanjiu pointed out in the Investor Relations Activity Record that in the first quarter of the company, except for individual varieties that were affected by the centralized procurement policy, other businesses and products have been recovering growth, and offline sales have returned to previous levels.
.
In addition, China Resources Sanjiu stated on the “Interaction Easy” that the company insists on innovation, transformation and upgrading, and continues to increase R&D investment.
In 2020, the company’s R&D investment is 581 million yuan, accounting for 4.
26% of operating revenue.
Currently, the company has 57 research projects, mainly in the fields of tumor, orthopedics, skin, respiratory and other fields.
Recently, China Resources Sanjiu pointed out in the Investor Relations Activity Record that in the first quarter of the company, except for individual varieties that were affected by the centralized procurement policy, other businesses and products have been recovering growth, and offline sales have returned to previous levels.
.
In addition, China Resources Sanjiu stated on the “Interaction Easy” that the company insists on innovation, transformation and upgrading, and continues to increase R&D investment.
In 2020, the company’s R&D investment is 581 million yuan, accounting for 4.
26% of operating revenue.
Currently, the company has 57 research projects, mainly in the fields of tumor, orthopedics, skin, respiratory and other fields.
Thermal Scene Biology
Net profit: 560 million to 660 million yuan
Year-on-year growth: 109126% ～128630%
On April 13th, Hotview Biotech disclosed its first-quarter performance forecast, with an estimated net profit of 560 million to 660 million yuan, a year-on-year increase of more than 1,000 times, and it has become the "pre-increasing king" of performance.
At the same time as the performance surged, the company's stock price also surged one after another, gaining 4 consecutive boards, which rose more than 130% in 5 days.
Hotview Biotech stated that in the first quarter of 2020, affected by the company's normal business cycle and the new crown epidemic, the company's operating performance was relatively small, resulting in a small comparison base with the first quarter of 2021.
In the first quarter of 2021, the company's new coronavirus 2019n-CoV antigen detection kit (anterior nasal cavity) and new coronavirus 2019n-CoV antigen detection kit (saliva), two new coronavirus antigen rapid detection reagent products, obtained German federal drugs and The medical equipment research institute (BfArM) is used for home free testing certification, which can be sold in German supermarkets, pharmacies, Internet stores, etc.
, which has led to an explosive growth of the company's foreign trade orders.
At the same time as the performance surged, the company's stock price also surged one after another, gaining 4 consecutive boards, which rose more than 130% in 5 days.
Hotview Biotech stated that in the first quarter of 2020, affected by the company's normal business cycle and the new crown epidemic, the company's operating performance was relatively small, resulting in a small comparison base with the first quarter of 2021.
In the first quarter of 2021, the company's new coronavirus 2019n-CoV antigen detection kit (anterior nasal cavity) and new coronavirus 2019n-CoV antigen detection kit (saliva), two new coronavirus antigen rapid detection reagent products, obtained German federal drugs and The medical equipment research institute (BfArM) is used for home free testing certification, which can be sold in German supermarkets, pharmacies, Internet stores, etc.
, which has led to an explosive growth of the company's foreign trade orders.
Source: Oriental Fortune.
com, Announcement of Listed Companies
com, Announcement of Listed Companies
Statistics are as of the close on the morning of April 16.
If there are any errors or omissions, please correct me.
If there are any errors or omissions, please correct me.
Medical Network, April 19, with the intensive disclosure of the 2020 annual reports of listed companies, the first quarter of 2021 transcripts will follow.
According to statistics, a total of 110 pharmaceutical companies in A-shares have disclosed their performance in the first quarter.
Three companies including Intech Healthcare and Daan Gene have net profits of over 1 billion yuan; 500 million to 1 billion yuan are Changchun High-tech, Yiling Pharmaceutical, 7 companies including China Resources Sanjiu and Harbin Sanlian; 52 companies including Kelun Pharmaceutical, Haisco and Zuoli Pharmaceutical have doubled, and Hotview Bio has soared 1,000 times, becoming the "pre-increasing king" of performance; Qianhong Pharmaceutical, 18 companies including Jinling Pharmaceutical turned losses into profits.
It is worth mentioning that there are currently 14 companies that are losing money, and only 2 companies are the first to lose money.
In the same period last year, 30 companies are the first to lose money.
Brokerage analysis pointed out that the first quarter of last year was affected by the epidemic and the performance of many listed companies was impacted.
Given the low base last year, it is a general consensus in the market that the performance forecast for the first quarter of this year will be better.
According to statistics, a total of 110 pharmaceutical companies in A-shares have disclosed their performance in the first quarter.
Three companies including Intech Healthcare and Daan Gene have net profits of over 1 billion yuan; 500 million to 1 billion yuan are Changchun High-tech, Yiling Pharmaceutical, 7 companies including China Resources Sanjiu and Harbin Sanlian; 52 companies including Kelun Pharmaceutical, Haisco and Zuoli Pharmaceutical have doubled, and Hotview Bio has soared 1,000 times, becoming the "pre-increasing king" of performance; Qianhong Pharmaceutical, 18 companies including Jinling Pharmaceutical turned losses into profits.
It is worth mentioning that there are currently 14 companies that are losing money, and only 2 companies are the first to lose money.
In the same period last year, 30 companies are the first to lose money.
Brokerage analysis pointed out that the first quarter of last year was affected by the epidemic and the performance of many listed companies was impacted.
Given the low base last year, it is a general consensus in the market that the performance forecast for the first quarter of this year will be better.
A-share pharmaceutical companies' performance in the first quarter of 2021
A-share pharmaceutical company's first quarter 2021 performance report
A-share pharmaceutical companies' performance forecast for the first quarter of 2021
90 % of the first quarter Announcement! 52 companies doubled, 18 companies turned losses, only 2 companies lost first
According to statistics, there are currently 110 pharmaceutical companies in A-shares that have disclosed their performance in the first quarter of 2021.
Among them, 15 have disclosed their quarterly reports, one is a performance report, and 94 are performance forecasts.
Three companies, including Intech Medical and Daan Gene, have a net profit of over 1 billion yuan; Changchun High-tech, Yiling Pharmaceutical, China Resources Sanjiu, Harbin Sanlian, etc.
, with a net profit of 500 million to 1 billion yuan; Kelun Pharmaceutical, Haisco 52 companies, including Zuoli Pharmaceuticals, doubled, and Hotview Biology surged 1,000 times, becoming the "pre-increasing king" of performance; 18 companies including Qianhong Pharmaceuticals and Jinling Pharmaceuticals turned losses into profits.
It is worth mentioning that there are currently 14 companies that are losing money, and only 2 companies are the first to lose money.
In the same period last year, 30 companies are the first to lose money.
Among them, 15 have disclosed their quarterly reports, one is a performance report, and 94 are performance forecasts.
Three companies, including Intech Medical and Daan Gene, have a net profit of over 1 billion yuan; Changchun High-tech, Yiling Pharmaceutical, China Resources Sanjiu, Harbin Sanlian, etc.
, with a net profit of 500 million to 1 billion yuan; Kelun Pharmaceutical, Haisco 52 companies, including Zuoli Pharmaceuticals, doubled, and Hotview Biology surged 1,000 times, becoming the "pre-increasing king" of performance; 18 companies including Qianhong Pharmaceuticals and Jinling Pharmaceuticals turned losses into profits.
It is worth mentioning that there are currently 14 companies that are losing money, and only 2 companies are the first to lose money.
In the same period last year, 30 companies are the first to lose money.
，，，，。，，，，，。
20215436，314.
4%；20202535。，，，，，2021。
4%；20202535。，，，，，2021。
，2020，，，2020。，2021，。2950～3800，207%～238%，2761。
、……5！1000
：8.
41～8.
95
41～8.
95
：55%～65%
，，。，202085.
77，16.
31%；30.
47，71.
64%，，、。，58.
03，20.
34%，27.
60，39.
66%；14.
33，43.
30%，4.
09，133.
88%。，“”，，，、。，21，42，（），。
77，16.
31%；30.
47，71.
64%，，、。，58.
03，20.
34%，27.
60，39.
66%；14.
33，43.
30%，4.
09，133.
88%。，“”，，，、。，21，42，（），。
：6.
57～7.
01
57～7.
01
：50%～60%
，，。，；，，。，1.
1、ⅢCDE，Ⅲ。
1、ⅢCDE，Ⅲ。
：6～7.
1
1
：12.
5%～33.
13%
5%～33.
13%
，，，，，，。，，，，。，“”，，，20205.
81，4.
26%。57，、、、。
81，4.
26%。57，、、、。
：5.
6～6.
6
6～6.
6
：109126%～128630%
413，，5.
6～6.
6，1000，“”。，，4，5130%。，2020，，2021。20212019n-CoV（）2019n-CoV（），（BfArM），、、，。
6～6.
6，1000，“”。，，4，5130%。，2020，，2021。20212019n-CoV（）2019n-CoV（），（BfArM），、、，。
：、
416，，。
419 2020，2021。，A110，、310；5～10、、、7；、、52，1000，“”；、18。，14，2，，30。，，，，。
A2021
A2021
A2021
9！52，18，2
9！52，18，2 ，A1102021，，15，1，94。、310；5～10、、、7；、、52，1000，“”；、18。，14，2，，30。
Brokerage analysis pointed out that the first quarter of last year was affected by the epidemic and the performance of many listed companies was impacted.
Given the low base last year, it is a general consensus in the market that the performance forecast for the first quarter of this year will be better.
Many pharmaceutical companies that have turned losses have stated in their announcements that during the same period last year, due to the impact of the new crown epidemic, the number of people going to hospitals for medical treatment decreased, which affected product sales.
As the epidemic was effectively controlled and prevention and control normalized, business sales have gradually recovered this year.
Hospital hospital hospitalGiven the low base last year, it is a general consensus in the market that the performance forecast for the first quarter of this year will be better.
Many pharmaceutical companies that have turned losses have stated in their announcements that during the same period last year, due to the impact of the new crown epidemic, the number of people going to hospitals for medical treatment decreased, which affected product sales.
As the epidemic was effectively controlled and prevention and control normalized, business sales have gradually recovered this year.
Qianhong Pharmaceutical's net profit in the first quarter of 2021 is expected to be 54.
36 million yuan, a year-on-year increase of 314.
4%; a loss of 25.
35 million yuan in the first quarter of 2020.
Qianhong Pharmaceutical said that due to the epidemic in the same period last year, the company's business was affected.
With the effective control of the epidemic, the company's business gradually returned to normal.
In the first quarter of 2021, the company's various businesses, especially the sales of preparations, increased significantly compared with the same period last year.
36 million yuan, a year-on-year increase of 314.
4%; a loss of 25.
35 million yuan in the first quarter of 2020.
Qianhong Pharmaceutical said that due to the epidemic in the same period last year, the company's business was affected.
With the effective control of the epidemic, the company's business gradually returned to normal.
In the first quarter of 2021, the company's various businesses, especially the sales of preparations, increased significantly compared with the same period last year.
Jinling Pharmaceuticals stated that the new crown epidemic broke out in early 2020, and the company's medical institutions invested various medical resources and medical staff to fight the new crown pneumonia epidemic.
Normal medical work was affected, resulting in a decline in the company's 2020 medical service revenue and profits.
With the effective control of the epidemic in my country, in the first quarter of 2021, the medical business of the company's medical institutions has basically returned to the normal level before the outbreak, and profits have increased compared with the same period of the previous year.
The net profit in the first quarter is estimated to be 29.
5 million to 38 million yuan, a year-on-year increase of 207% to 238%, and a net profit loss of 27.
61 million yuan in the same period last year.
Normal medical work was affected, resulting in a decline in the company's 2020 medical service revenue and profits.
With the effective control of the epidemic in my country, in the first quarter of 2021, the medical business of the company's medical institutions has basically returned to the normal level before the outbreak, and profits have increased compared with the same period of the previous year.
The net profit in the first quarter is estimated to be 29.
5 million to 38 million yuan, a year-on-year increase of 207% to 238%, and a net profit loss of 27.
61 million yuan in the same period last year.
Changchun Hi-tech, China Resources Sanjiu.
.
.
Net profit exceeds 500 million! This one skyrocketed 1,000 times
Changchun Hi-tech, China Resources Sanjiu. .
.
Net profit exceeds 500 million! This one skyrocketed 1,000 times
.
.
Net profit exceeds 500 million! This one skyrocketed 1,000 times
Changchun High-tech
Changchun High-tech Net profit: 841 million to 895 million yuan
Net profit: 841 million to 895 million yuan Year-on-year growth: 55% ~ 65%
Year-on-year growth: 55% ~ 65% Regarding the substantial growth in performance in the first quarter, Changchun Hi-tech pointed out that it was mainly due to the income growth of the backbone pharmaceutical companies.
According to the Changchun High New Year Report, the company's operating income in 2020 was 8.
577 billion yuan, a year-on-year increase of 16.
31%; net profit was 3.
047 billion yuan, a year-on-year increase of 71.
64%.
The company and its subsidiaries are operating steadily, and the revenue and net profit of key pharmaceutical companies continue to grow.
Among them, the subsidiary Jinsai Pharmaceutical achieved revenue of 5.
803 billion yuan, a year-on-year increase of 20.
34%, and a net profit of 2.
76 billion yuan, a year-on-year increase of 39.
66%; subsidiary Baike Biotechnology achieved revenue of 1.
433 billion yuan, a year-on-year increase of 43.
30%, and a net profit of 409 million Yuan, a year-on-year increase of 133.
88%.
Ma Ji, chairman of Changchun Hi-tech, stated that “market expansion and innovative R&D” are the company’s primary strategic goals, and the introduction of high-end talents is the focus of internal management.
The market share of the products, the promotion of new indications and the enrichment of the product line.
It is worth mentioning that Beike Biotech’s application for listing on the Science and Technology Innovation Board was approved on February 1 this year, and its prospectus (registration draft) was disclosed on April 2, and it is currently in the registration stage.
According to the Changchun High New Year Report, the company's operating income in 2020 was 8.
577 billion yuan, a year-on-year increase of 16.
31%; net profit was 3.
047 billion yuan, a year-on-year increase of 71.
64%.
The company and its subsidiaries are operating steadily, and the revenue and net profit of key pharmaceutical companies continue to grow.
Among them, the subsidiary Jinsai Pharmaceutical achieved revenue of 5.
803 billion yuan, a year-on-year increase of 20.
34%, and a net profit of 2.
76 billion yuan, a year-on-year increase of 39.
66%; subsidiary Baike Biotechnology achieved revenue of 1.
433 billion yuan, a year-on-year increase of 43.
30%, and a net profit of 409 million Yuan, a year-on-year increase of 133.
88%.
Ma Ji, chairman of Changchun Hi-tech, stated that “market expansion and innovative R&D” are the company’s primary strategic goals, and the introduction of high-end talents is the focus of internal management.
The market share of the products, the promotion of new indications and the enrichment of the product line.
It is worth mentioning that Beike Biotech’s application for listing on the Science and Technology Innovation Board was approved on February 1 this year, and its prospectus (registration draft) was disclosed on April 2, and it is currently in the registration stage.
Yiling Pharmaceutical
Yiling Pharmaceutical Net profit: 677 million to 701 million yuan
Net profit: 677 million to 701 million yuan Year-on-year growth: 50% ～60%
Year-on-year growth: 50% ～60% Yiling Pharmaceutical said that on the one hand, the company's winning the first prize of the National Science and Technology Progress Award has gradually shown its influence on the company's cardiovascular and cerebrovascular products market, and market demand has grown steadily.
At the same time, with the adjustment of the company’s sales strategy and the completion of the optimization of the marketing organization structure, sales revenue has achieved substantial year-on-year growth; on the other hand, the brand awareness of Lianhua Qingwen’s products has been greatly improved, the market share has continued to increase, and sales revenue has achieved a higher level than the same period last year.
Good growth.
A few days ago, the Phase III clinical trial program of Yiling Pharmaceutical's 1.
1 category innovative drug aniprofen injection for the treatment of postoperative moderate and severe pain completed the registration and publicity of the CDE drug clinical trial registration and information disclosure platform, and the phase III clinical trial can be initiated.
test.
At the same time, with the adjustment of the company’s sales strategy and the completion of the optimization of the marketing organization structure, sales revenue has achieved substantial year-on-year growth; on the other hand, the brand awareness of Lianhua Qingwen’s products has been greatly improved, the market share has continued to increase, and sales revenue has achieved a higher level than the same period last year.
Good growth.
A few days ago, the Phase III clinical trial program of Yiling Pharmaceutical's 1.
1 category innovative drug aniprofen injection for the treatment of postoperative moderate and severe pain completed the registration and publicity of the CDE drug clinical trial registration and information disclosure platform, and the phase III clinical trial can be initiated.
test.
China Resources Sanjiu
China Resources Sanjiu Net profit: 600 million to 710 million yuan
Net profit: 600 million to 710 million yuanYear- on-year growth: 12.
5% ～33.
13%
Year- on-year growth: 12. 5% ～33.
13%
5% ～33.
13%
Regarding the performance growth in the first quarter, China Resources Sanjiu stated that the company conformed to the development trend of the industry, continued to carry out innovation, transformation and upgrading, continuously optimized product structure, strengthened brand building, and promoted profitability.
Recently, China Resources Sanjiu pointed out in the Investor Relations Activity Record that in the first quarter of the company, except for individual varieties that were affected by the centralized procurement policy, other businesses and products have been recovering growth, and offline sales have returned to previous levels.
.
In addition, China Resources Sanjiu stated on the “Interaction Easy” that the company insists on innovation, transformation and upgrading, and continues to increase R&D investment.
In 2020, the company’s R&D investment is 581 million yuan, accounting for 4.
26% of operating revenue.
Currently, the company has 57 research projects, mainly in the fields of tumor, orthopedics, skin, respiratory and other fields.
Recently, China Resources Sanjiu pointed out in the Investor Relations Activity Record that in the first quarter of the company, except for individual varieties that were affected by the centralized procurement policy, other businesses and products have been recovering growth, and offline sales have returned to previous levels.
.
In addition, China Resources Sanjiu stated on the “Interaction Easy” that the company insists on innovation, transformation and upgrading, and continues to increase R&D investment.
In 2020, the company’s R&D investment is 581 million yuan, accounting for 4.
26% of operating revenue.
Currently, the company has 57 research projects, mainly in the fields of tumor, orthopedics, skin, respiratory and other fields.
Thermal Scene Biology
Thermal Scene Biology Net profit: 560 million to 660 million yuan
Net profit: 560 million to 660 million yuan Year-on-year growth: 109126% ～128630%
Year-on-year growth: 109126% ～128630% On April 13th, Hotview Biotech disclosed its first-quarter performance forecast, with an estimated net profit of 560 million to 660 million yuan, a year-on-year increase of more than 1,000 times, and it has become the "pre-increasing king" of performance.
At the same time as the performance surged, the company's stock price also surged one after another, gaining 4 consecutive boards, which rose more than 130% in 5 days.
Hotview Biotech stated that in the first quarter of 2020, affected by the company's normal business cycle and the new crown epidemic, the company's operating performance was relatively small, resulting in a small comparison base with the first quarter of 2021.
In the first quarter of 2021, the company's new coronavirus 2019n-CoV antigen detection kit (anterior nasal cavity) and new coronavirus 2019n-CoV antigen detection kit (saliva), two new coronavirus antigen rapid detection reagent products, obtained German federal drugs and The medical equipment research institute (BfArM) is used for home free testing certification, which can be sold in German supermarkets, pharmacies, Internet stores, etc.
, which has led to an explosive growth of the company's foreign trade orders.
Medicines Medicines Medicines Medical Devices Medical Devices Medical DevicesAt the same time as the performance surged, the company's stock price also surged one after another, gaining 4 consecutive boards, which rose more than 130% in 5 days.
Hotview Biotech stated that in the first quarter of 2020, affected by the company's normal business cycle and the new crown epidemic, the company's operating performance was relatively small, resulting in a small comparison base with the first quarter of 2021.
In the first quarter of 2021, the company's new coronavirus 2019n-CoV antigen detection kit (anterior nasal cavity) and new coronavirus 2019n-CoV antigen detection kit (saliva), two new coronavirus antigen rapid detection reagent products, obtained German federal drugs and The medical equipment research institute (BfArM) is used for home free testing certification, which can be sold in German supermarkets, pharmacies, Internet stores, etc.
, which has led to an explosive growth of the company's foreign trade orders.
Source: Oriental Fortune.
com, Announcement of Listed Companies
com, Announcement of Listed Companies
Statistics are as of the close on the morning of April 16.
If there are any errors or omissions, please correct me.
If there are any errors or omissions, please correct me.
